<http://schema.org/articleBody>
"The Fraunhofer USA Center for Molecular Biotechnology announced on Tuesday that it won a $9.9 million contract from the National Institute of Allergy and Infectious Disease toward developing the next generation of anthrax vaccines.<br /><br />The contract, which includes a $1.76 million first-year phase, is meant to support the advanced development of candidate vaccine technologies and components that speed up the human immune response after intentional or natural exposure to anthrax-causing Bacillus anthracis, <a href=\"http://www.genengnews.com/\">Genetic Engineering &amp; Biotechnology News</a> reports.<br /><br />The contract covers multiple activities for FhCMB, including preclinical activities, formulation development and stability, protein purification, agro infiltration, biomass generation, pre-IND activities and IND submission. The contract ends with the option to conduct a Phase I clinical trial. The activities will result from successful completion of prior milestones and the exercising of contract options.<br /><br />Upon the completion of clinical trials, FhCMB will work closely with iBio, its commercialization partner, to meet the needs of the U.S. government by advancing the vaccine.<br /><br />Isconova, a Swedish-owned company, will develop an adjuvant to combine with the FhCMB antigen.<br /><br />\"(The combined product) has the potential for an improved vaccine,\" Vidadi Yusibov, the Fraunhofer center's executive director, said, according to <a href=\"http://www.genengnews.com/\">Genetic Engineering &amp; Biotechnology News</a>."^^<http://www.w3.org/2001/XMLSchema#string>
<http://bioprepwatch.com/stories/510509565-fhcmb-wins-9-9-million-contract-from-nih-for-anthrax-vaccines>